On-X Life Technologies, Inc. Release: Four Clinical Trials Document the On-X Heart Valve’s Exceptional Clinical Performance  
6/27/2011 9:12:09 AM

AUSTIN, Texas--(BUSINESS WIRE)--On-X® Life Technologies, Inc. (On-X LTI) announced today that four clinical trial reports, documenting the On-X® Prosthetic Heart Valve’s extraordinary performance, will be presented at the upcoming meeting of the Society for Heart Valve Disease in Barcelona, Spain being held June 25-28, 2011. The reports will include interim clinical results from the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT), which is being conducted in 36 major institutions in the United States, a comparison of the On-X heart valve with three competitive mechanical valves in Australia, a Ten-year Multiple Center European Study and a Ten-year Study in Poorly Controlled Anticoagulated Patients in South Africa. All four studies provide evidence of the continuing superior performance of the On-X Prosthetic Heart Valve.